77results about How to "Lower serum uric acid levels" patented technology

The invention disclosed the application of celery seed coumarins and flavanoid in preparing arthrifuge, anti-inflammatory agent or health food, which belongs to the natural occurring drugs and medical technology domain. The coumarins and flavanoid is the extract from acetic ether. The preparing method includes the following steps: selecting 10kg celery dry seed, adding 15-20 times of 75-95%(V / V) as the seed or extracting with 4-5 times of 75-95%(V / V) alcohol at higher temperature, heating for 1-1.5h every time; vacuum condensing the extracts until nearly all the alcohol is away; adding 1-2 times of water, extracting with 1 / 3 volume of the diluted solution sherwood oil (60-90DEG C) for 2-3 times; reclaiming the sherwood oil; extracting the water layer with 1 / 3 volume of acetic ether for 4 times; reclaiming the acetic ether to get the extracts. The invention has very simple preparing technologies; the product in the invention has obvious anti-inflammatory function; it can also decrease the amount of serum uric acid of rats.

An extract of mulberry twigs is dislcosed, which can be used to prepare the food or the medicine to cure hyperuricemia and gout diseases. The said extract is prepared from mulberry twigs through extracting in solvent (aqueous solution of alcohol, chloroform, acetone, etc) at 10-100 deg.C more than one time, mergint the liquid extracts, recovering solvent, regulating pH value to 7.5-9.5, centrifugal separation to obtain supernatant, regulating pH value to 4-6, deposition, water washing wand drying. Several other approaches for purifying it are also disclosed.

The present invention relates to a novel purpose of mangiferin compound for preventing and remedying hyperuricemia and gout. A study shows that the mangiferin compound has very strong anti-gout effect; 0.002mmol / kg (0.78mg / kg) of the dosage can reduce the serum uric acid level of a mouse with the hyperuricemia obviously; the mangiferin compound has higher activity than allopurinol and has little toxic and side effect; the maximum gastric infusion tolerance dose of the mouse is 47.4mmol / kg (20g / kg), which is lower than that of current clinical applied anti-gout medicines, such as colchicines, the allopurinol, sulphinpyrazone, etc.; the present invention can be applied to prepare for oral anti-gout medicines and health care products.

The invention relates to a medicinal composition for treating hyperuricemia, which comprises Febuxostat or derivate thereof, benzbromarone and a pharmaceutically acceptable medicinal carrier, whereinthe ratio in weight portion of the Febuxostat or derivate thereof to the benzbromarone to the pharmaceutically acceptable medicinal carrier is 1:1-4:0.5-100. The medicinal composition can provide extremely beneficial effects of treating the hyperuricemia. Pharmacological tests prove that the medicinal composition has obviously synergistic action, can quickly reduce the concentration of purine trione in blood serum, remarkably improves effect of treating the hyperuricemia, greatly reduces medicament dosage of single component simultaneously, and effectively reduces toxic and side effect of medicament.

The invention belongs to the field of medicines and discloses a mango leaf extract and application thereof. Mango leaves are subjected to refluxing extraction and concentration via aliphatic alcohol with 1-4 carbon atoms, and the obtained product is extracted and purified via low-polarity organic solvent and is refined to obtain the mango leaf extract. The mango leaf extract disclosed by the invention contains mangiferin and homomangiferin which are at specific proportion, and is better than a mangiferin monomer in the solubility. Pharmacological research proves that the mango leaf extract has the effects of lowering the level of serum uric acid of a hyperuricemia mice and reducing blood sugar, and is better than the mangiferin. Therefore, the invention provides application of the mango leaf extract provided by the invention to the medicine for preventing or treating the metabolic syndrome.

The invention discloses application of a compound 3,5,2',4'-tetrahydroxy chalcone in preparation of a drug for preventing and treating hyperuricemia and gout, relating to the application of drugs containing organic components. The compound obviously inhibits the activity of xanthine oxidase in vitro, wherein IC50 has the dosage of 22.5 mu mol / L and is a competitive inhibitor. In-vivo research shows that the compound has stronger gout resistant role, can obviously lower the uric acid level of serum of a rat with hyperuricemia induced by potassium oxonate or hypoxanthine by using 14.6 mu mol / kg (3.98mg / kg) dose, has less toxic and side effects, the maximum tolerance dose for intragastric administration of the rat being 5.0g / kg and obviously lower toxicity than gout resisting drugs used clinically at present, such as allopurinol, colchicin, benzbromarone, and the like, and can be used for preparing drugs and health care products for preventing and treating hyperuricemia and gout.

The invention discloses a dendrobium officinale leaf extract with a uric acid reducing function and application of the dendrobium officinale leaf extract. The dendrobium officinale leaf extract is prepared through the following steps: cleaning and drying the dendrobium officinale leaves; mechanically pulverizing; carrying out reflux extraction by a 0-30V% ethanol solution for 1-3 times, wherein the time of each reflux extraction is 1-3h and the dosage of each reflux extraction is 5-20 times of the medicine weight; combining the filtrates; recovering the ethanol; and carrying out vacuum concentration to obtain the dendrobium officinale leaf extract. The dendrobium officinale leaf extract can be used for preventing medicines or food for preventing and treating hyperuricemia; the dendrobium officinale leaf extract relies on the dendrobium officinale leaves to develop the effects of the dendrobium officinale leaves, so that the new medicinal resources of the dendrobium officinale are expanded and the resource waste is decreased at the same time.

Provided is a method for obtaining a lactic acid bacterium having a property of reducing a serum uric acid level. The present invention relates to: a method for screening for a lactic acid bacterium, which comprises determining the amount of a purine body incorporated in each of lactic acid bacteria in a culture medium containing the purine body and then screening for a lactic acid bacterium having a property of trapping the purine body among the lactic acid bacteria employing the amount as a measure; and a purine body trapping agent for reducing a serum uric acid level, which comprises a lactic acid bacterium obtained by the method.

Provided herein are methods of treating gout, treating hyperuricemia, lowering serum uric acid, or the like with compounds of formula (I) have the following structure Further, provided herein are compositions comprising a compound of formula (I).

The invention discloses application of a gallate derivative which has a formula (I) and a pharmaceutically acceptable salt thereof to preparation of a medicine for treating hyperuricemia. The gallate derivative has a strong effect of inhibiting xanthine oxidase in vitro, can be used for reducing the level of serum uric acid of a mouse with hyperuricemia significantly, is dose dependent and can be used for treating hyperuricemia and gout or gout complications caused by hyperuricemia as a potential xanthine oxidase inhibitor and a potential uric acid lowering medicine. The formula (I) is as shown in the specification.

The invention relates to a chrysin derivative and preparation thereof and application thereof in treating hyperuricemia, and belongs to the field of pharmaceutical synthesis. By using easily-obtained natural product chrysin as a starting material and selectively introducing active functional groups containing fluorine atoms, chrysin derivatives (I) and (II) are synthesized; a synthetic method is simple and is well operable and high in reaction yield, the obtained chrysin derivatives has significantly enhanced anti-hyperuricemia activity when compared to lead compound chrysin and is useful in treating hyperuricemia.

The invention discloses lactobacillus rhamnosus CCFM1131 for relieving hyperuricemia, and belongs to the technical field of microorganisms. The lactobacillus rhamnosus CCFM1131 can reduce the serum uric acid level of a hyperuricemia mouse, inhibit the xanthine oxidase (XOD) activity of serum and the liver, and reduce the occurrence of hyperuricemia and gout; the lactobacillus rhamnosus CCFM1131 can be used for down-regulating serum blood sugar, down-regulating serum total triglyceride (TG), down-regulating serum total cholesterol (TC) level and inhibiting serum alkaline phosphatase (ALP) activity; in addition, the lactobacillus rhamnosus CCFM1131 can promote the expression of the ileum uric acid transporter ABCG2. Besides, the lactobacillus rhamnosus CCFM1131 can tolerate gastrointestinaltract environment, can be used for preparing functional microbial inoculants, foods and medicines for relieving hyperuricemia and gout, and has a wide application prospect.

The invention discloses application of a marihuana extract in preparation of gout treating medicine. Inventors find that tetrahydrocannabinol and cannabidiol have the quite strong gout resisting effect after being mixed according to the specific ratio for the first time, the hyperuricemia mouse serum uric acid level can be remarkably lowered, no obvious influence is produced to the normal mouse serum uric acid level, toe swelling induced by sodium urate can be remarkably restrained, activity is similar to that of allopurinol, and the toxic and side effect is small. The marihuana extract has the obvious gout treating and preventing effect. The invention further provides a gout treating medicinal preparation of the marihuana extract and a corresponding dosage form thereof. Various kinds of medicine with different dosage forms can be used clinically through a conventional preparation method, and use is convenient.

The invention discloses the application of a flos chrysanthemi indici extract. Linarin is contained in the flos chrysanthemi indici extract, the mass percent of the linarin is not smaller than 50 percent, the application of the flos chrysanthemi indici extract is as follows: the flos chrysanthemi indici extract is used for preventing or curing hyperuricemia. According to the invention, through the combination of the linarin contained in the flos chrysanthemi indici extract, the characteristic of lowering xanthine oxidase activity can be achieved, and the flos chrysanthemi indici extract can be used for preventing or curing hyperuricemia, can remarkably lower the serum uric acid level of a model rat, can lower the levels of serum creatinine and urea nitrogen, has the advantages of easiness in component separation, controllability in quality, low additive dose, remarkable effects and the like, and has a great and profound significance in improving human health.

The invention discloses application of a digallate derivative which has a formula (I) and a pharmaceutically acceptable salt thereof to preparation of a medicine for treating hyperuricemia. The digallate derivative has a strong effect of inhibiting xanthine oxidase in vitro, can be used for reducing the level of serum uric acid of a mouse with hyperuricemia significantly, is dose dependent and can be used for treating hyperuricemia and gout or gout complications caused by hyperuricemia as a potential xanthine oxidase inhibitor and a potential uric acid lowering medicine.

The invention discloses a traditional Chinese medicine compound preparation for treating gout and a preparation method thereof. The traditional Chinese medicine compound preparation comprises glabrous greenbrier rhizome, orientvine vine, Fangji root, phellodendron bark, pseudo-ginseng, desmodium, Dioscorea collettii hook var, achyranthes root and red peony root and has the following main functions: clearing of heat, diuresis promotion, dampness elimination, detoxification, blood circulation invigoration and dissipating of binds. The traditional Chinese medicine compound preparation is used for hyperuricemia, gouty arthritis, downward flow of damp-heat and toxin and blood stasis syndrome. Symptoms include redness, swelling, heat pain and limited activity of attacked joints, fever, headache, hypodynamia, a red tongue, yellow greasy furred tongue and slippery pulses.

The invention provides an eurycoma longifolia jack (eurycoma longifolia jack) extract and a preparation method and application thereof. The eurycoma longifolia jack extract contains a eurycoma longifolia jack diterpene component of which the percentage by weight is 85%-95%. The eurycoma longifolia jack diterpene component disclosed by the invention has the effects of reducing the serum uric acid level of an experiment high-uric-acid animal model and promoting excretion of uric acid, and is hopeful to be further developed into a medicine for treating high uric acid.

The present invention relates to apigenin derivatives and an application of the apigenin derivatives in treatment of hyperuricemia, and belongs to the field of medicinal chemistry. The invention discloses the apigenin derivatives shown in a formula (I), and the invention also discloses the application of the apigenin derivatives in preparation of anti-hyperuricemia medicines. According to the invention, the novel apigenin derivatives are synthesized by taking natural product apigenin which is easy to obtain as a starting raw material, and the synthetic method is simple, and has the better operability and reaction yield; and the prepared apigenin derivatives have obvious anti-hyperuricemic activity, and are used for treating the hyperuricemia and gout diseases.

The invention relates to a composition for reducing hyperuricemia and its preparation method and an application, and belongs to the field of a healthcare food. The composition is prepared from cordyceps militaris extractive and needle cherry powder at the weight ratio of 1-50: 1-20. The cordyceps militaris product for reducing hyperuricemia can be applied to the assistant treatment of hyperuricemia, and can reduce the toxic side effect of drug treatment as well as the treatment cost of the hyperuricemia patient; the composition is good for reducing the morbidity of gout and other chronic disease; therefore, the composition has good market prospect.

The present invention discloses a saury Maillard peptide with antihyperuricemic activity and its preparation method and application, with the method comprising the following steps: mincing a saury, adding water, heating, agitating, adjusting a pH value to 4.2, separating by centrifugation, and collecting the precipitate; adding water, proteases and amino acids to the precipitate, adjusting a pH value to 7.0, hydrolyzing, adding a reducing sugar to cause a reaction, centrifuging and collecting a supernatant which is saury Maillard peptide; and spray drying the peptide liquid to obtain a dry powder. The method of the present invention realizes the continuous action of enzymolysis and Maillard reaction to prepare the Maillard peptide, not only simplifying the production process, shortening the production cycle, and reducing the production costs, but also significantly enhancing the antihyperuricemic activity of the produced Maillard peptide. Animal experiments in rats showed that the obtained Maillard peptide prepared by the method of the present invention could significantly decrease the level of serum uric acid in rats, and display certain protective effect in their kidney.

The invention relates to a preparation method and an application of kelp extract for effectively reducing uric acid, and belongs to the technical field of biological medicines. The preparation method particularly includes the steps: soaking dried kelps in 4 DEG C distilled water for 24-36 hours; draining and shearing the kelps; adding ethyl alcohol according to the mass-volume ratio of 1:6-10; sufficiently homogenizing the ethyl alcohol; stirring and soaking the kelps at the temperature of 4 DEG C for 48-72 hours after ultrasonic treatment; pumping filter liquor to 1 / 3 volume in vacuum; performing ultra-filtration concentration and vacuum freeze-drying to obtain the uric acid reducing kelp extract. By the aid of the kelp extract, the expression level of urate decorporation genes UAT can be remarkably improved, the expression level of urate reabsorption genes URAT can be reduced, and the content of serum uric acid is remarkably reduced on the premise of protecting renal functions.

The invention relates to a gout-relieving tea containing chicory and dandelions. The tea is a powdery health-care tea prepared by the following steps: selecting raw materials including chicory, dandelions, Chinese wolfberry fruits, kudzuvine roots, mulberry leaves, coix seeds and desertliving cistanche, removing impurities, baking and curing the clear raw materials, crushing the raw materials intofine powder, and performing mixing, drying, sterilization and packaging. The powder mixture of the gout-relieving tea containing chicory and dandelions comprises the following components in parts byweight: 15-40 parts of chicory powder, 15-35 parts of dandelion powder, 15-40 parts of Chinese wolfberry fruits, 8-20 parts of kudzuvine root powder, 8-20 parts of mulberry leaf powder, 5-15 parts ofcoix seed powder and 4-10 parts of desertliving cistanche powder. The gout-relieving tea containing chicory and dandelions adopts medicinal and edible foods, contains a plurality of nutrient components, has two edible and medicinal functions, can effectively improve the uric acid level of a human body, has obvious effect on relieving the symptoms of gouty arthritis, is convenient to drink, and isa health tea which can be eaten frequently. The gout-relieving tea containing chicory and dandelions has simple production process and low cost, and is suitable for large-scale production.

The invention discloses a traditional Chinese medicinal composition for treating gout and a preparation method of same and belongs to the field of traditional Chinese medicines. Traditional Chinese medicine ternate buttercup root, buzhaye, Chinese knotweed, holly root, long pepper and apocynum venetum as raw materials are combined to form an active component; and then the active component and a general accessory of the medicament are combined to form an oral preparation. The traditional Chinese medicinal preparation can achieve the function of treating the gout.

The invention discloses an application of cannabidiol in preparing medicines for treating gout. The inventor discovers that cannabidiol has a quite strong gout resisting effect for the first time, and the cannabidiol is capable of significantly reducing the serum uric acid level of a mouse with hyperuricemia, avoiding obvious influence on the serum uric acid level of a normal mouse and significantly reducing and inhibiting swelling toes caused by sodium urate; the activity of the cannabidiol is better than that of allopurinol; and the cannabidiol is low in toxic and side effects. The invention also provides a pharmaceutical preparation of the cannabidiol for treating the gout and a corresponding dosage form of the pharmaceutical preparation; and by virtue of a conventional preparation method, the cannabidiol can be prepared into clinically applicable medicines in various dosage forms, and the medicines are convenient to use.

The invention belongs to the technical field of pharmacy, and in particular relates to novel application of (2E,6E)-2-(3,5-dimethoxy phenylidene)-6-(4-chlorphenyl methylene)cyclohexanone and a derivative thereof. With a moderate / high dose, the (2E,6E)-2-(3,5-dimethoxy phenylidene)-6-(4-chlorphenyl methylene)cyclohexanone and the derivative thereof provided by the invention can remarkably reduce the acute gouty arthritis mouse ankle joint swelling degree and the serum uric acid level, meanwhile have very good NLRP3 and TLR4 dual inhibition activity, have effects better than that of a positive control dexamethasone, can be used for preparing medicines for treating hyperuricemia or acute gouty arthritis, and is small in side effect and high in safety.

The invention belongs to the field of a medicine treating gout diseases, and particularly relates to a compound celery seed tablet assisting gout treatment and a preparation method thereof. The compound celery seed tablet comprises celery seed, lobed kudzuvine root, pericarpium citri reticulatae, artemisia argyi and folium perillae with the weight ratio being 24:5:5:5:5. The preparation method comprises the following steps: (1), weighing raw materials, crushing, and sieving the raw materials with a 100-mesh sieve; (2), performing ethanol extraction, and performing ultrasonic-assisted extraction; (3), performing filtrate decompression and ethanol removal, so as to obtain primary extract, and performing low temperature sterilization, so as to obtain compound celery seed thick extract; (4), adding beta-cyclodextrin, starch and microcrystalline cellulose, then spraying ethanol, and performing spray drying, so as to obtain powder particles; adding sodium carboxymethyl starch and magnesium stearate into the powder particles, and performing tabletting, so as to obtain the target product compound celery seed tablet. The compound celery seed tablet can effectively reduce a uric acid index,resist gout treatment, reduce gout relapse and relieve gout symptoms, and does not have any toxic and side effect.

The invention relates to novel application of garcinia mangostana L pericarp extract in prevention and treatment of hyperuricemia and gout. Researches find that the garcinia mangostana L pericarp extract is capable of in-vitro inhibiting activities of xanthine oxidase, and IC50 of the garcinia mangostana L pericarp extract is 31.39ml / L. in vivo studies show that the garcinia mangostana L pericarpextract has a strong uric acid lowering effect, by feeding 20mg / kg of the garcinia mangostana L pericarp extract to a mouse with oteracil potassium induced hyperuricemia intragastrically, the serum uric acid level of the mouse can be obviously lowered, which means the uric acid lowering effect of the garcinia mangostana L pericarp extract is related to inhibition of the xanthine oxidase activities, and generation of the uric acid is inhibited. By feeding 2.0g / kg of the garcinia mangostana L pericarp extract to the mouse intragastrically, no animal dies, and no obvious toxic and side effect isfound, so that the garcinia mangostana L pericarp extract can be used for preparing oral medicaments for treating the gout and the hyperuricemia and medicament and health care products for diseases related to the hyperuricemia.

An extract of mulberry twigs is dislcosed, which can be used to prepare the food or the medicine to cure hyperuricemia and gout diseases. The said extract is prepared from mulberry twigs through extracting in solvent (aqueous solution of alcohol, chloroform, acetone, etc) at 10-100 deg.C more than one time, mergint the liquid extracts, recovering solvent, regulating pH value to 7.5-9.5, centrifugal separation to obtain supernatant, regulating pH value to 4-6, deposition, water washing wand drying. Several other approaches for purifying it are also disclosed.

The invention disclosed the application of celery seed coumarins and flavanoid in preparing arthrifuge, anti-inflammatory agent or health food, which belongs to the natural occurring drugs and medical technology domain. The coumarins and flavanoid is the extract from acetic ether. The preparing method includes the following steps: selecting 10kg celery dry seed, adding 15-20 times of 75-95%(V / V) as the seed or extracting with 4-5 times of 75-95%(V / V) alcohol at higher temperature, heating for 1-1.5h every time; vacuum condensing the extracts until nearly all the alcohol is away; adding 1-2 times of water, extracting with 1 / 3 volume of the diluted solution sherwood oil (60-90DEG C) for 2-3 times; reclaiming the sherwood oil; extracting the water layer with 1 / 3 volume of acetic ether for 4 times; reclaiming the acetic ether to get the extracts. The invention has very simple preparing technologies; the product in the invention has obvious anti-inflammatory function; it can also decrease the amount of serum uric acid of rats.

The invention relates to application of a compound in preparation of a drug for treating gout. The compound has a structure as shown in formula I. Through experiments, it shows that the compound can inhibit URAT1, reabsorption of uric acid is stopped, discharge of the uric acid of rats can be promoted, the serum urate levels is reduced, sodium urate induced THP-1 CELL IL-1 beta and TNF-alpha secretion can further be inhibited obviously, the degree of rat ankle swelling caused by sodium urate is reduced, inflammatory response is reduced, and arthralgia is relieved. It shows that the compound has effect of treating hyperuricemia and / or gout and has high application value.